Skip to main content
. 2017 Apr 3;8(23):37605–37618. doi: 10.18632/oncotarget.16790

Table 1. Patient demographics and baseline characteristics.

Category N = 177
n (%)
Sex
 Male 102 (57.6)
 Female 75 (42.4)
Age (years)
 Median (range) 71 (48–86)
 ≥ 75 years 39 (22.0)
Type of myeloma
 IgG 108 (61.0)
 IgA 43 (24.3)
 IgM 2 (1.1)
 Light chain 20 (11.3)
 Non-secretory 4 (2.3)
Stage - Durie–Salmon Staging System
 I 13 (7.3)
 II 51 (28.8)
 III 113 (63.8)
Stage - International Staging System
 I 22 (12.6)
 II 70 (40.0)
 III 83 (47.4)
Skeletal lesions
 0 33 (18.6)
 1–2 44 (24.9)
 ≥ 3 80 (45.2)
 Unknown 20 (11.3)
ECOG-PS
 0 11 (6.2)
 1 104 (58.8)
 2 42 (23.7)
 3 19 (10.7)
 4 1 (0.6)
Serum β2-microglobulin (mg/L)
 Median (range) 5.3 (0–35.3)
 < 2.5 17 (9.7)
 2.5–5.5 75 (42.9)
 > 5.5 83 (47.4)
Albumin (g/dL)
 Median (range) 3.3 (1.0–5.1)
 < 3.5 107 (61.1)
 ≥ 3.5 68 (38.9)
Creatinine clearance (mL/min)
 Median (range) 43.6 (5.8–106.6)
 < 60 129 (73.7)
 ≥ 60 46 (26.3)
Comorbidity
 No 40 (22.6)
 Yesb 137 (77.4)
 Allergy 1 (0.6)
 Renal impairment 31 (17.5)
 Hepatic impairment 5 (2.8)
 Others 129 (72.9)
Cytogenetics abnormality category
 Standard risk 121 (68.4)
 High riska 24 (13.6)
 Deletion 13 by karyotypeb 17 (9.6)
 Deletion 17p by FISHb 7 (4.0)
 t(4:14) by FISHb 6 (3.4)
 t(14:16) by FISHb 4 (2.3)
 Hypodiploidy by karyotypeb 2 (1.1)
 Test not done 32 (18.1)

a High risk cytogenetics: deletion 13 by karyotype, deletion 17p by FISH/karyotype, t(4;14), t(14;16), and hypodiploidy.

b Multiple counting.

FISH, fluorescence in situ hybridization.